The Truth About Hydrazine Sulfate -
Dr. Gold Speaks

6/7/05

GENERAL INFORMATION

Hydrazine sulfate is an anti-cachexia drug which acts to reverse the metabolic processes of debilitation and weight loss in cancer and secondarily acts to stabilize or regress tumors. Hydrazine sulfate is a monoamine oxidase (MAO) inhibitor and is incompatible with tranquilizers, barbiturates, alcohol and other central nervous system depressants. Foods high in tyramine, such as aged cheeses and fermented products, are also incompatible with MAO inhibitors. The use of tranquilizers, barbiturates and/or alcoholic beverages with hydrazine sulfate destroys the efficacy of this drug and increases patient morbidity.

The U.S. National Cancer Institute (NCI)-published studies of hydrazine sulfate (Journal of Clinical Oncology, June 1994), which were reported as negative; the NCI denied the concurrent use of tranquilizers, with the exception of the short-term use of prochlorperazine (Compazine). However, under pressure of an investigation of the NCI studies by the U.S. General Accounting Office ordered by Congress, the NCI in a subsequent paper (Journal of Clinical Oncology, June 1995) admitted to the widespread use of both benzodiazepine and phenothiazine tranquilizers, in 94% of all patients. Moreover, approximately half of these patients were given these tranquilizers on a long-term basis, and some on a continual basis. It was further admitted by the NCI that concomitant drug use (such as tranquilizers, alcohol, barbiturates, etc.) was not computerized and patient records of such drug use were "incomplete."

There is an abundance of published, positive, peer-reviewed studies on hydrazine sulfate in the medical literature. These data emanate both from the United States (randomized, double-blind, placebo-controlled studies) and Russia (large-scale, Phase II multicentric controlled clinical trials).

Hydrazine sulfate has been demonstrated to produce only few and fleeting side effects. There have been no instances of bone-marrow, heart, lung, kidney or immune system toxicity, or death. Hydrazine sulfate has never been shown to be carcinogenic in humans.

For further information please have your HEALTH CARE PROFESSIONAL (no patients or individuals, please) call the institute.

DOCTORS AND HEALTH CARE PROFESSIONALS: PLEASE CALL BETWEEN 9:00 AM AND 5:00 PM EASTERN TIME, WEEKDAYS, (315) 472-6616, 472-6618, 472-2229.

COLLECTION OF ARTICLES | HOW TO CONTACT SCRI

IMPORTANT EDITORIAL. November 21, 2002.
It has come to the Syracuse Cancer Research Institute’s attention that a well-known and respected medical journal has issued a warning to the public on its Internet website that hydrazine sulfate is potentially ‘dangerous’ to the liver and kidney, having induced “fatal hepatorenal failure” in a single patient. Although the journal chose to editorialize this ‘Brief Communication' -- and make it all the more important to the public -- there is only one thing ‘wrong’ with this statement: there is no proof that the patient in question ever took hydrazine sulfate. The authors of this ‘Brief Communication’ state: “We could not obtain samples of the product he [the patient] ingested for laboratory analysis.” This means that there was no possibility of a direct examination of what it was the patient was taking. The authors further state: “His blood was not tested for the presence of hydrazine.” This statement cannot be easily reconciled, for there are simple spectrofluorometric blood tests that can confirm even the tiniest residues of hydrazine sulfate ingested even months prior.

It must be stressed that no medical journal anywhere -- of high repute or not -- would publish an article and editorial based on only one case, calling attention of the medical and lay public to the potential toxicity of a drug gaining in common use, without incontrovertible, verifiable, iron-clad proof that the patient in question ever took the drug in the first place. No journal would thereby violate its integrity. Or its ethics. No journal would have the temerity to publish an article having far-reaching repercussions on the public health, without absolute proof of its basic, fundamental assumptions.

The authors of the article and editorial, basing their warning of hydrazine sulfate toxicity to the liver and kidney on but one unverifiable patient, were nevertheless conversant with the large-scale National Cancer Institute-sponsored studies of hydrazine sulfate -- in which hundreds of patients verifiably received the drug -- which showed the complete absence of any organ toxicity, including liver and kidney: “There were no significant differences between the protocol treatment arms [hydrazine sulfate and placebo] with regard to myelodepression, gastrointestinal toxicity, renal toxicity, cardiopulmonary toxicity, or neurotoxicity.”

(Contrast this situation -- in which a cancer ‘drug-alert’ is disseminated worldwide via the Internet based on unconfirmed use in a single patient -- with the tens of thousands of authenticated drug deaths due to cancer chemotherapy each year. Yet no journal has seen fit to issue an Internet warning to the public of this truly legitimate hazard.)

Hydrazine sulfate has been in clinical use since 1973. Thousands of study patients have been published in the medical literature. And many more thousands the world over have been treated by their individual doctors. There has not been a single case of hepatorenal failure ever reported.

The Syracuse Cancer Research Institute therefore judges that the ‘drug-alert,’ recently issued in regard to hydrazine sulfate, is simply not credible.

A collection of articles on Hydrazine Sulfate has been available on this site since 23 October 1996.

The Syracuse Cancer Research Institute asks your help in its life-sustaining activities. Now, more than ever, the institute must expand its research and outreach programs. Your tax-deductible contributions are vital to this effort and serve to enhance the welfare and lives of cancer patients everywhere. Please send your gifts to:

Syracuse Cancer Research Institute,
600 East Genesee Street,
Syracuse, NY 13202.

All contributions are greatly appreciated and will be acknowledged

This page is designed and hosted by NGEN, and is the property of the Syracuse Cancer Research Institute. © 1996-2004, Syracuse Cancer Research Institute. All rights reserved.
Last modified on 7 June 2005